Abstract
AMCP convened a panel of clinical and managed care experts to identify insights regarding the prevalence, clinical manifestations, and management approaches for immunoglobulin E–mediated food allergies. This article aims to summarize expert perspectives on health care system challenges and areas of agreement concerning the management of food allergies, and to advance payers’ understanding of their role in supporting health care for patients with food allergies. Food allergy management requires dietary modification and is associated with significant patient and caregiver burdens. Emerging therapies provide hope for those living with food allergies but will likely lead to a rise in health plan pharmacy expenses. In considering the value of new treatments, it is important to consider the total cost of care and the value of preventing anaphylaxis and enhancing the patient’s quality of life. Several challenges remain in identifying the appropriate patient population for treatment with newer agents and in optimizing treatment outcomes. Addressing health disparities will require standardized clinical protocols, better access to specialized allergy care, and management of comorbid conditions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S1-S10 |
| Journal | Journal of Managed Care and Specialty Pharmacy |
| Volume | 30 |
| Issue number | 8-a |
| DOIs | |
| State | Published - Aug 1 2024 |
Funding
This supplement was conceptualized by AMCP. The AMCP Market Insights Program described in this supplement was supported through funding by Genentech. Dr Richardson discloses support for medical writing from AMCP made to Impact Education, LLC. Dr Vickery discloses grants or contracts from the National Institutes of Health and National Institute of Allergy and Infectious Diseases, Genentech, Aimmune Therapeutics, Aravax, Alladapt, AstraZeneca, DBV, Moonlight Therapeutics, Novartis, Regeneron, and Siolta, made to his institution. Dr Vickery also discloses consulting fees from Aimmune Therapeutics, Aravax, DBV, Genentech, IgGenix, Novartis, Parexel, Reacta, Regeneron Pharmaceuticals, Revolo, Sanofi, and Stallergenes Greer. Dr Vick-ery discloses stock options in Moonlight Therapeutics. Dr Gupta discloses grants or contracts from National Institutes of Health (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), Food Allergy Research & Education, Sunshine Charitable Foundation, Genentech, Novartis, The Walder Foundation, and the Melchiorre Family Foundation. Dr Gupta discloses consulting fees from Genentech, Novartis, Aimmune Therapeutics, Allergenis, and Food Allergy Research & Education. Dr Gupta discloses patents planned, issued, or pending for Yobee (US Patent No. 11103544) and ownership interest in Yobee Care, Inc. Mr. Goldstein discloses support and honoraria from AMCP for the manuscript and activity. Ms Wescott discloses honoraria from AMCP for lectures, presentations, speakers bureaus, and support for attending meetings and/or travel. Dr Gandhi discloses payment for speaking and support to attend the IgNS 12th National Conference in Denver, CO. Dr Gandhi discloses paid participation in an AMCP advisory board, and his volunteer role as the Florida AMCP Affiliate Secretary. Ms Winders discloses honoraria for consultant and speaking from AstraZeneca, GSK, Genentech, Roche, Sanofi, and Regeneron Pharmaceuticals. Dr Kobernick and Dr Chan report no disclosures.
ASJC Scopus subject areas
- Pharmacy
- Pharmaceutical Science
- Health Policy
